Old Web
English
Sign In
Acemap
>
authorDetail
>
Michel Dapoigny
Michel Dapoigny
University of Auvergne
Disease
Internal medicine
Gastroenterology
Vedolizumab
in patient
3
Papers
4
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Réseau ARA public-privé de « Centres APPI » (Activité Physique -Prévention -Impact) pour la prévention du cancer par l'activité physique
2021
A. Serova-Erard
S. Rey
L. Nicolas
P. Galvin
A. Ait-Omar-Bourkeb
C. Legouge
M. Lepage
P. Dessenne
J. Scanzi
M. Helyon
C. Petorin
A. Vimal
S Mansard
Armando Abergel
Michel Dapoigny
Jacques-Olivier Bay
M. D’incan
Igor Tauveron
Denis Pezet
R. Benamouzig
Laurent Gerbaud
Martine Duclos
F. Cornelis
Show All
Source
Cite
Save
Citations (0)
Prokaryotic and Eukaryotic Fecal Microbiota in Irritable Bowel Syndrome Patients and Healthy Individuals Colonized With Blastocystis.
2021
Frontiers in Microbiology
Céline Nourrisson
Julien Scanzi
Julie Brunet
Frédéric Delbac
Michel Dapoigny
Philippe Poirier
Show All
Source
Cite
Save
Citations (0)
Comparison of short- and long-term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor therapy.
2021
Alimentary Pharmacology & Therapeutics
Luc Manlay
Gilles Boschetti
Bruno Pereira
Bernard Flourié
Michel Dapoigny
M. Reymond
Elisa Sollelis
Mathilde Boube
Anthony Buisson
Stéphane Nancey
Show All
Source
Cite
Save
Citations (4)
1